SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

(2021) Sara E. Oliver et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

(2021) Katherine R W Emary et al.   LANCET

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

(2021) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates

(2021) Yong Bok Seo et al.   Vaccines

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

(2021) Robert W. Frenck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID‐19 reinfection in a healthcare worker after exposure with high dose of virus: A case report

(2021) Shahram Ahmadian et al.   Clinical Case Reports

Peoples’ attitude toward COVID-19 vaccine, acceptance, and social trust among African and Middle East countries

(2021) Nasim Asadi Faezi et al.   Health Promotion Perspectives

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

(2020) Amy S. Espeseth et al.   npj Vaccines

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

(2020) Gregory D. Sempowski et al.   CELL

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

(2020) Shuai Xia et al.   CELL RESEARCH

Herd Immunity: Understanding COVID-19

(2020) Haley E. Randolph et al.   IMMUNITY

The early landscape of COVID‐19 vaccine development in the UK and rest of the world

(2020) Hannah R Sharpe et al.   IMMUNOLOGY

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

(2020) Daniela Calina et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Estimating case fatality rates of COVID-19

(2020) Piotr Spychalski et al.   LANCET INFECTIOUS DISEASES

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

(2020) Shibo Jiang   NATURE

The proximal origin of SARS-CoV-2

(2020) Kristian G. Andersen et al.   NATURE MEDICINE

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic

(2020) Andrew M. South et al.   Nature Reviews Nephrology

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Immunogenicity of a DNA vaccine candidate for COVID-19

(2020) Trevor R. F. Smith et al.   Nature Communications

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

(2020) Longping V. Tse et al.   Frontiers in Microbiology

Advances in research on ACE2 as a receptor for 2019-nCoV

(2020) Jie Wu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2

(2020) Kevin V. Morris   MOLECULAR THERAPY

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

(2020) Noe B. Mercado et al.   NATURE

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

Next-generation vaccine platforms for COVID-19

(2020) Debby van Riel et al.   NATURE MATERIALS

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

(2020) Muhammad Adnan Shereen et al.   Journal of Advanced Research

Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective

(2020) Yashpal Singh Malik et al.   Pathogens

Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)

(2020) Pourya Gholizadeh et al.   Journal of Inflammation Research

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

(2020) Ahmad Abu Turab Naqvi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

(2020) Ahmed O. Hassan et al.   CELL

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

(2020) Tarek Mohamed Abd El-Aziz et al.   INFECTION GENETICS AND EVOLUTION

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with Covid-19

(2020) Hadis Fathizadeh et al.   MICROBIAL PATHOGENESIS

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

UniProt: the universal protein knowledgebase in 2021

(2020) et al.   NUCLEIC ACIDS RESEARCH

Identification of potential lockdown areas during COVID-19 transmission in Punjab, Pakistan

(2020) U. Saeed et al.   PUBLIC HEALTH

Non-viral COVID-19 vaccine delivery systems

(2020) Kyung Soo Park et al.   ADVANCED DRUG DELIVERY REVIEWS

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

(2020) Cole J. Batty et al.   ADVANCED DRUG DELIVERY REVIEWS

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas

(2019) Danielle Adney et al.   Viruses-Basel

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

(2019) Robert A. Feldman et al.   VACCINE

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

(2019) Kimberly J. Hassett et al.   Molecular Therapy-Nucleic Acids

Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia

(2019) Ding An et al.   EBioMedicine

Study of virulence factor of Candida species in oral lesions and its association with potentially malignant and malignant lesions

(2018) Graciela del Valle Castillo et al.   ARCHIVES OF ORAL BIOLOGY

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

(2018) Sofia E. Magnusson et al.   IMMUNOLOGIC RESEARCH

Chitin/silk fibroin/TiO 2 bio-nanocomposite as a biocompatible wound dressing bandage with strong antimicrobial activity

(2018) Mojtaba Ghanbari Mehrabani et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

(2018) Norbert Pardi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Review of DNA Vaccines Against Influenza

(2018) Leo Yi Yang Lee et al.   Frontiers in Immunology

Novel Platforms for the Development of a Universal Influenza Vaccine

(2018) Arun Kumar et al.   Frontiers in Immunology

The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection

(2017) Lan Jiaming et al.   VACCINE

Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study

(2016) Xiaozhou Fan et al.   GUT

Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins

(2016) Xiuyuan Ou et al.   JOURNAL OF VIROLOGY

Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study

(2016) Andrea Quagliariello et al.   Nutrients

Codon Optimality Is a Major Determinant of mRNA Stability

(2015) Vladimir Presnyak et al.   CELL

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

(2015) Naru Zhang et al.   Cellular & Molecular Immunology

Molecular mechanisms for enhanced DNA vaccine immunogenicity

(2015) Lei Li et al.   Expert Review of Vaccines

Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

(2015) Xiaojuan Guo et al.   IMMUNOLOGY

Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen

(2014) Jiaming Lan et al.   PLoS One

Recombinant vaccines and the development of new vaccine strategies

(2012) I.P. Nascimento et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

(2012) Iris Delrue et al.   Expert Review of Vaccines

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

Developing mRNA-vaccine technologies

(2012) Thomas Schlake et al.   RNA Biology

What you always needed to know about electroporation based DNA vaccines

(2012) Anita Gothelf et al.   Human Vaccines & Immunotherapeutics

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

(2011) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

Isoelectric points of viruses

(2010) B. Michen et al.   JOURNAL OF APPLIED MICROBIOLOGY

Pyrosequencing analysis of the Oral Microflora of healthy adults

(2009) B.J.F. Keijser et al.   JOURNAL OF DENTAL RESEARCH

Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5

(2009) Shinya Abe et al.   JOURNAL OF GENE MEDICINE

Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection

(2009) J. Chen et al.   JOURNAL OF VIROLOGY

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

(2008) Rafick-Pierre Sekaly   JOURNAL OF EXPERIMENTAL MEDICINE

Designed recombinant adenovirus type 5 vector induced envelope-specific CD8+cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1

(2008) Takehiro Ura et al.   JOURNAL OF GENE MEDICINE